August 25, 2026 · Phase 3 readout
NVS Phase 3 readout: a positive outcome, +6.0%
+6.0%Novartis AG (NVS) →
On August 25, 2026, JDQ443 — Novartis AG (Non-Small Cell Lung Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +6.0% in the window around the event.
The move
$152.06
1d before
$161.25
Event day
$162.46
1d after
$159.99
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+3.2% expected); the stock actually moved +6.0%. Model confidence at the time: 82%.
See the full scored track recordPre-catalyst setup
-1.5%
30-day run-up
2324%
30-day volatility
0.9×
volume spike